VVS

General Information


DRACP ID  DRACP02742

Peptide Name   VVS

Sequence  VEEVSKKVEEVSKKVEEVSKKVEEVSKKVEEVSKKXK

Sequence Length  37

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP Lipopeptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Huh-7 Adult hepatocellular carcinoma; Adult hepatocellular carcinoma Carcinoma CC50=74.5±6.8 µM CCK-8 assay 48 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Acetylation

C-terminal Modification  CH3(CH2)14CONH2, Hexadecanamide

Other Modification  X= β-Ala

Chiral  L



Physicochemical Information


Formula  C181H317N47O61

Absent amino acids  ACDFGHILMNPQRTWY

Common amino acids  K

Mass  488004

Pl  9.13

Basic residues  11

Acidic residues  10

Hydrophobic residues  10

Net charge  1

Boman Index  -10575

Hydrophobicity  -107.84

Aliphatic Index  78.38

Half Life 
  /

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  5

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 30192544

Title  De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery

Doi 10.1021/acs.jmedchem.8b00890

Year  2018

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_15185

DRACP is developed by Dr.Zheng's team.